How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comModes Of Radiation Decay
Radiation Decay is the process in which all unstable radioactive atoms give off energy, in the form of radiation, in order to become stable (non-radioactive). 4 of the modes of radiation decay are discussed below
Loading...
Isotopes
Radioisotopes are the unstable (radioactive) atoms that are linked to a ligand (delivery system) that are then used to either image a cancer or treat a cancer depending on the properties of each radioisotope as discussed below
ACTINIUM-225
Radioisotope: Ac-225
Theranostic Role: Therapeutic Agent & SPECT Imaging
T1/2 (Half-Life): 9.9 Days
Decay Mode: ALPHA, GAMMA
Energy: 5.8-8.4 MeV
Range: 47-85 micrometers
Decay Daughters: Ra225, Fr221, At217, Bi213, 209, Po213, 209, TL209, 205
Status: Clinical Trials Only
ASTATINE-211
Radioisotope: At-211
Theranostic Role: Therapeutic Agent
T1/2 (Half-Life): 7.2 hours
Decay Mode: ALPHA, ELECTRON CAPTURE
Energy: 2 Alpha particles 5.87 & 7.45 MeV
Range: 50-100 micrometers
Decay Daughters: Bi207, Po211
Status: Clinical Trials Only
CARBON-11
Radioisotope: C-11
Theranostic Role: PET Imaging, SPECT Imaging
T1/2 (Half-Life): 20.4 Min
Decay Mode: POSITRON β+ (99.8%), ELECTRON CAPTURE (0.2%), GAMMA
Energy: max 0.96 MeV, mean 386 keV, Gamma 511 keV
Range: N/A
Decay Daughters: B11 (Stable)
Status: FDA Approval: Carbon 11 Choline (2012)
Copper-61
NEWRadioisotope: Cu-61
Theranostic Role: Imaging
T1/2 (Half-Life): 3.33 Hr
Decay Mode: Positron Emission (61%)
Energy: 2,237.5 keV
Range: 1.3mm in water
Decay Daughters: Nickel-61
Status: Clinical Trials
COPPER-64
Radioisotope: Cu-64
Theranostic Role: PET Imaging
T1/2 (Half-Life): 12.7 Hours
Decay Mode: POSITRON β+, BETA, Electron Capture, GAMMA
Energy: 0.65 MeV, Gamma 511 keV
Range: max 2.5mm, mean 0.7mm
Decay Daughters: Ni64 (Stable), Zn64 (Stable)
Status: FDA Approval: DETECTNET®
COPPER-67
Radioisotope: Cu-67
Theranostic Role: Therapeutic Agent & SPECT Imaging
T1/2 (Half-Life): 62 Hours
Decay Mode: BETA, GAMMA
Energy: Beta: max 575 keV, mean 154 keV, Gamma: 184 keV (44%). 91/93 keV (21%)
Range: In Tissue: 0.6-2.2 mm
Decay Daughters: Zn67 (Stable)
Status: Clinical Trials Only
FLUORINE-18
Radioisotope: F-18
Theranostic Role: PET Imaging
T1/2 (Half-Life): 1.8 Hours
Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
Energy: Eβ+ 635 keV
Range: N/A
Decay Daughters: O18 (Stable)
Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
GALLIUM-68
Radioisotope: Ga-68
Theranostic Role: PET Imaging
T1/2 (Half-Life): 68 minutes
Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
Range: N/A
Decay Daughters: Zn68 (Stable)
Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
INDIUM-111
Radioisotope: In-111
Theranostic Role: SPECT Imaging
T1/2 (Half-Life): 2.8 Days
Decay Mode: ELECTRON CAPTURE, GAMMA
Energy: 173 keV, 247 keV
Range: N/A
Decay Daughters: Cd111 (Stable)
Status: FDA Approvals: ONCOSCINT® (1992), OCTREOSCAN® (1994)
IODINE-123
Radioisotope: I-123
Theranostic Role: SPECT Imaging
T1/2 (Half-Life): 13.2 Hours
Decay Mode: BETA, GAMMA
Energy: Beta: 127 keV (14%), 154 keV (2%) Gamma: 539 keV (1%), 159 keV (83%), 27 keV (71%)
Range: N/A
Decay Daughters: Te123 (Stable)
Status: FDA Approvals: DATSCAN®(2011), ADREVIEW® (2008)
IODINE-131
Radioisotope: I-131
Theranostic Role: Therapeutic Agent & SPECT Imaging
T1/2 (Half-Life): 8 Days
Decay Mode: BETA, GAMMA
Energy: βeta max 0.6 MeV Gamma 364 keV
Range: In Tissue: 0.8 -2.1 mm
Decay Daughters: Xe131
Status: FDA Approval: 1951-First FDA Approved Radiopharmaceutical), AZEDRA® (2018)
LEAD-203
Radioisotope: Pb-203
Theranostic Role: SPECT Imaging
T1/2 (Half-Life): 52 Hours
Decay Mode: ELECTRON CAPTURE, GAMMA
Energy: Gamma 279keV (81%)
Range: N/A
Decay Daughters: Tl203 (Stable)
Status: Clinical Trials Only
LEAD-212
Radioisotope: Pb-212
Theranostic Role: Therapeutic Agent
T1/2 (Half-Life): 10.6 Hours
Decay Mode: ALPHA, BETA, GAMMA
Energy: Alpha 6 MeV (25%), 6 MeV (10%), 8.7 MeV (71%) Beta 1.5 MeV (18%), 1.8 MeV (20%), 2.2 MeV (53%) Gamma 583 keV (30%), 2.6 MeV (36%)
Range: 50-100 micrometers
Decay Daughters: Bi212, Tl208, Po212, Pb208
Status: Clinical Trials Only, 2024 FDA Breakthrough Therapy Designation for ALPHAMEDIX™ GEP-NET Tumors
LUTETIUM-177
Radioisotope: Lu-177
Theranostic Role: Therapeutic Agent & SPECT Imaging
T1/2 (Half-Life): 6.7 Days
Decay Mode: BETA, GAMMA
Energy: Eβeta max 497 keV, Gamma 113-208 keV
Range: In Tissue: 0.25-2mm
Decay Daughters: Hf177
Status: FDA Approvals: PLUVICTO® (2022), LUTATHERA® (2017)
PHOSPHORUS-32
Radioisotope: P-32
Theranostic Role: Therapeutic Agent, SPECT Imaging
T1/2 (Half-Life): 14.3 Days
Decay Mode: BETA
Energy: Max: 1.71 MeV, Avg: 694 keV
Range: Air: 20 feet, Water/Tissue: 8.7mm
Decay Daughters: S32 (Stable)
Status: Clinical Trials Only
RADIUM-223
Radioisotope: Ra-223
Theranostic Role: Therapeutic Agent
T1/2 (Half-Life): 11.4 Days
Decay Mode: ALPHA, BETA, GAMMA
Energy: Alpha (95%) 5-7.5 MeV Beta (3.6%) 445-492 keV Gamma (1%) 82-402 keV
Range: In Tissue <100 micrometers
Decay Daughters: 4 alpha daughters: Rn219, Po211,215, Bi211
Status: FDA Approval: XOFIGO® (2013)
RHENIUM-186
Radioisotope: Re-186
Theranostic Role: Therapeutic Agent and SPECT Imaging
T1/2 (Half-Life): 3.7 Days
Decay Mode: ELECTRON CAPTURE (7.5%), BETA (92.5%), GAMMA
Energy: EC 0.58 MeV; Beta mean 346 keV, Gamma 137 keV
Range: In Tissue: 4.5mm
Decay Daughters: Os186 (Stable), W186 (Stable)
Status: Clinical Trials Only, 2023 FDA Orphan Drug Status for Breast Cancer with Leptomeningeal Metastases
RHENIUM-188
Radioisotope: Re-188
Theranostic Role: Therapeutic Agent & SPECT Imaging
T1/2 (Half-Life): 17 Hours
Decay Mode: BETA, GAMMA
Energy: Max 2.1 MeV, Avg 784 keV Gamma: 155 keV (15%)
Range: In Tissue: 11mm
Decay Daughters: Os188 (Stable)
Status: ONCOBETA® (German) Rhenium-SCT® for non-melanoma skin cancer treatment
SAMARIUM-153
Radioisotope: Sm153
Theranostic Role: Therapeutic
T1/2 (Half-Life): 1.9 Days
Decay Mode: BETA, GAMMA
Energy: Beta: Max 808 keV Gamma: 103 keV (28%)
Range: 0.6 mm
Decay Daughters: Eu153 (Stable)
Status: FDA Approval: QUADRAMET® (1997)
TECHNETIUM-99m
Radioisotope: Tc-99m
Theranostic Role: SPECT Imaging
T1/2 (Half-Life): 6 Hours
Decay Mode: GAMMA
Energy: 140 keV (89.1%)
Range: N/A
Decay Daughters: Tc99
Status: FDA Approval: First in 1980’s
TERBIUM-161
Radioisotope: Tb-161
Theranostic Role: Therapeutic Agent & SPECT Imaging
T1/2 (Half-Life): 6.9 Days
Decay Mode: BETA, GAMMA
Energy: Beta: Avg 154 keV Gamma: 49 keV (17%), 75 keV (10%)
Range: 0.5-30 micrometers
Decay Daughters: Dy161 (Stable)
Status: Clinical Trials Only
THORIUM-227
Radioisotope: Th-227
Theranostic Role: Therapeutic Agent
T1/2 (Half-Life): 19 Days
Decay Mode: ALPHA, BETA
Energy: Alpha 5.9 MeV (Ra223), 5.7 MeV ( Rn219), Total 5 Alpha particles (Total 34MeV)
Range: <0.1 mm
Decay Daughters: Ra223, Rn219, Po215, Pb211, Bi211, Tl207 Pb207 (Stable)
Status: Clinical Trials Only
YTTRIUM-90
Radioisotope: Y-90
Theranostic Role: Therapeutic Agent, SPECT Imaging & PET Imaging
T1/2 (Half-Life): 2.7 Days
Decay Mode: BETA
Energy: max 2.2 MeV
Range: In Tissue: Avg 2.5 mm, Max 11 mm; In Air: 35 feet
Decay Daughters: Zr90 (Stable)
Status: FDA Approvals: SIR-SPHERES® (2000), THERASPHERES® (2021)
ZIRCONIUM-89
Radioisotope: Zr89
Theranostic Role: PET Imaging
T1/2 (Half-Life): 78 Hours
Decay Mode: POSITRON β+ (22%), ELECTRON CAPTURE (76%), GAMMA
Energy: max 0.9 MeV, E mean 397 keV, Gamma 511 keV
Range: N/A
Decay Daughters: Y89 (Stable)
Status: Clinical Trials Only
Share your feedback
Help us improve your experience